62%of patients lost ≥5% body weight SUSTAIN-1 trial, 1mg dose
4.5 kgavg weight loss at 30 weeks SUSTAIN-1 trial
1.9%A1C reduction at 1mg dose SUSTAIN trials
26%CV risk reduction vs placebo SUSTAIN-6 trial
FDA-approved GLP-1
Once-weekly · Semaglutide up to 2mg
GLP-1 WEIGHT LOSS INJECTION
Ozempic® (Semaglutide) Buy Online for Weight Loss
62% of patients lost ≥5% body weight — SUSTAIN-1 phase 3 trial data
Ozempic is a once-weekly semaglutide injection that helps regulate blood sugar and suppress appetite
through GLP-1 receptor activation. In the SUSTAIN-1 phase 3 trial (30 weeks), patients on 1mg
semaglutide lost an average of 4.5 kg (about 10 lbs) compared to 1 kg on placebo — and 52–62%
of patients lost at least 5% of their starting body weight. Ozempic is sourced through Vitercure's
licensed US, UK and Canadian partner pharmacies.
All GLP-1 prescriptions on Vitercure require a clinical assessment. Your prescriber may recommend
Ozempic, Wegovy®,
Mounjaro® or another
treatment depending on your health history and goals.
One-time Ozempic pen packs — No automatic subscription
Compare strengths, countries and pen counts below.
Transparent pricing from US, UK and Canada-sourced pens. Your dose and refill plan are set by your prescriber.
Select pen strength and quantity. Your dose and titration are confirmed by your licensed prescriber.
$388.99
One-time medication cost from this source pharmacy. Telehealth visit and labs may be billed separately.
United Kingdom — 4 mg pen packs
Select pen strength and quantity. Your dose and titration are confirmed by your licensed prescriber.
$388.99
One-time medication cost from this source pharmacy. Telehealth visit and labs may be billed separately.
United States — 4 mg pen packs
Select pen strength and quantity. Your dose and titration are confirmed by your licensed prescriber.
$379.79
One-time medication cost from this source pharmacy. Telehealth visit and labs may be billed separately.
Number of packs
HIPAA-compliant and 256-bit encrypted. A valid prescription is required.
Licensed US, UK & Canadian partner pharmacies
HIPAA-secure telehealth
Cold-chain temperature-controlled shipping
About Ozempic® (Semaglutide)
Ozempic contains semaglutide — a GLP-1 receptor agonist that mimics a naturally occurring gut hormone
to regulate blood sugar, slow stomach emptying and reduce appetite. It is FDA-approved for adults with
type 2 diabetes and is widely used in medically supervised weight management programs. The same active
ingredient in a higher dose (2.4mg) is sold as Wegovy®,
which is approved specifically for chronic weight management.
How Ozempic works
Pancreas: Stimulates insulin secretion when blood glucose is elevated and suppresses inappropriate glucagon release.
Stomach: Slows gastric emptying, prolonging fullness after meals and reducing snacking between them.
Brain: Acts on hypothalamic appetite centers to reduce reward-driven eating and food cravings.
Heart: SUSTAIN-6 demonstrated a 26% reduction in major cardiovascular events vs placebo in high-risk patients with type 2 diabetes.
Patient outcomes reported on Ozempic
Individual results vary. These represent reported patient outcomes. Consult your prescriber for personalized expectations.
TM
"Lost 28 lbs over 5 months. My A1C went from 8.2 to 6.7. Ozempic genuinely changed my relationship with food."
−28 lbs · 5 months
CL
"The appetite suppression kicked in within 2 weeks. Down 22 lbs in 4 months — and my blood pressure is better too."
−22 lbs · 4 months
RA
"I'd been trying to lose weight for years. Ozempic got me 35 lbs down in 7 months without feeling deprived."
−35 lbs · 7 months
Ozempic Weight Loss Results — SUSTAIN Trial Data
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial program was a series
of phase 3 studies evaluating semaglutide across different doses, comparators and patient populations over 30–104 weeks.
Ozempic SUSTAIN trial weight loss and A1C outcomes by dose
Dose
Avg weight loss
Patients losing ≥5%
A1C reduction
Placebo
~1 kg
~15–20%
~0.1%
0.5mg semaglutide
~3.5 kg
52%
1.5%
1mg semaglutide (Ozempic)
~4.5 kg (~10 lbs)
62%
1.9%
2mg semaglutide (Ozempic)
~6.1 kg (~13 lbs)
~70%
2.2%
Source: SUSTAIN-1 through SUSTAIN-7 trial program. Results at 30 weeks with diet and exercise. Individual results vary.
SUSTAIN-6 — Cardiovascular Outcomes Trial
SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk. Semaglutide 0.5mg and 1mg
reduced the rate of major adverse cardiovascular events — nonfatal heart attack, nonfatal stroke or cardiovascular death —
by 26% compared to placebo over 104 weeks. This was the first phase 3 CV outcomes trial for once-weekly semaglutide.
Source: Marso SP et al. N Engl J Med. 2016;375:1834–1844. SUSTAIN-6.
Ozempic weight loss timeline — what to expect
Timeframe
What typically happens
Weeks 1–4
0.25mg starter dose. Some appetite changes begin. Nausea most common in this window. Weight loss of 1–3 lbs typical.
Month 2
Dose rises to 0.5mg. Appetite suppression more noticeable. Cumulative 3–6 lbs weight loss typical.
Months 3–5
Dose at 1mg if tolerated. Significant appetite reduction in most patients. 7–12 lbs total loss typical.
Month 6–12
Continued progress toward plateau. SUSTAIN-1 average at 30 weeks: 4.5 kg at 1mg (~10 lbs); up to 6.1 kg at 2mg.
Timeline is approximate and varies by dose, lifestyle factors and individual response.
Is Ozempic or Wegovy more effective for weight loss?
Wegovy® is more effective
for weight loss than Ozempic at standard diabetes doses. This is because Wegovy delivers semaglutide at up to
2.4mg per week — higher than Ozempic's 2mg maximum — and is specifically formulated for chronic weight management.
In the STEP-1 trial, Wegovy at 2.4mg produced 15.3% average body weight loss over 68 weeks, compared to roughly
6–9% with Ozempic at diabetes doses in the SUSTAIN trials. If weight loss is your primary goal, your prescriber
may recommend Wegovy over Ozempic.
Ozempic vs Wegovy vs Mounjaro — Key Differences
All three are injectable incretin therapies, but they differ in mechanism, approved indication, maximum dose and
weight loss outcomes. Your prescriber will decide which is right based on your diagnosis, other medications,
insurance coverage and weight loss goals.
Comparison of Ozempic, Wegovy and Mounjaro for weight loss
This comparison is educational and does not replace medical advice. Your prescriber selects the most appropriate option for your specific health profile.
Can you switch from Ozempic to Wegovy?
Yes, switching from Ozempic to Wegovy®
is possible if weight loss is your primary goal and you have been using Ozempic for that purpose. Switching
should always be done under clinician guidance to ensure the dose escalation is safe and side effects are managed.
If you are taking Ozempic specifically for type 2 diabetes, you would need to discuss the change with your
diabetes specialist, as Wegovy is not a diabetes treatment.
How to Use Ozempic
Administration basics
Form: Pre-filled subcutaneous injection pen.
Frequency: Once weekly, same day each week.
Sites: Abdomen, thigh or upper arm — rotate each week.
Starter; minimizes GI side effects during adjustment.
5+
0.5 mg once weekly
Maintenance for many patients. Blood sugar monitored.
If needed after 4+ weeks
1 mg once weekly
Increased if additional blood sugar control is required.
Maximum
2 mg once weekly
Highest approved Ozempic dose — highest weight loss outcomes in SUSTAIN trials.
What to do if you miss a dose
If fewer than 5 days have passed since your missed dose, inject as soon as you remember then continue on your
usual schedule. If more than 5 days have passed, skip the missed dose entirely and take your next one on the
usual day. Never double dose.
Step-by-step injection guide
Check the pen label and inspect the solution — it should be clear and colorless.
Attach a new needle by pushing it straight onto the pen and remove both caps.
Prime a new pen by selecting the flow check dose first.
Turn the dose counter to your prescribed dose.
Insert the needle into your skin at the injection site.
Press and hold the dose button until the counter returns to 0.
Count slowly to 6 before removing the needle.
Dispose of the needle in a sharps container. Replace the pen cap.
Important Safety Information for Ozempic
This is not complete safety information. Always review the full Prescribing Information and Medication Guide and speak with a licensed healthcare professional before starting or changing any medication.
Do not use Ozempic if:
You or a family member has a history of medullary thyroid carcinoma (MTC).
You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You are allergic to semaglutide or any Ozempic ingredient.
You have diabetic ketoacidosis (DKA) or type 1 diabetes.
Common side effects
Nausea, vomiting, diarrhea, constipation, stomach pain and injection-site reactions are most common, especially during dose escalation. More serious risks — pancreatitis, gallbladder disease, kidney problems and low blood sugar with other diabetes medicines — should be discussed with your prescriber before starting.
Alcohol and Ozempic
There are no known direct interactions between Ozempic and alcohol, but alcohol can worsen nausea and stomach upset — side effects already common with semaglutide — and may increase the risk of low blood sugar if you have diabetes. Light use may be acceptable; discuss your specific situation with your clinician.
Call your healthcare provider immediately if you have severe stomach pain, signs of allergic reaction, symptoms of very low blood sugar, or any serious side effects your clinician has told you to watch for.
Ozempic FAQ — Frequently Asked Questions
In the SUSTAIN-1 trial (30 weeks), patients on 1mg semaglutide (Ozempic) lost an average of 4.5 kg (~10 lbs),
with 52–62% losing at least 5% of their starting body weight. At the 2mg dose, average loss was around 6.1 kg
(~13 lbs). For weight loss specifically, Wegovy® (2.4mg semaglutide)
produces significantly greater results — up to 15.3% body weight loss over 68 weeks.
In the first month on Ozempic, most patients are on the 0.25mg starter dose, which minimizes side effects
but produces modest weight loss — typically 1–3 lbs. By month two at 0.5mg, loss accelerates. Overall weight
reduction averages about 1–2% of body weight per month once at a therapeutic dose, depending on diet and
activity. Results vary significantly by individual.
Both contain semaglutide but are different products. Ozempic is approved for type 2 diabetes at doses up to
2mg per week. Wegovy® is approved
specifically for chronic weight management at a higher maximum dose of 2.4mg per week. Wegovy produces
greater average weight loss in clinical trials. Your prescriber can help you decide which is more appropriate.
Yes. Switching between GLP-1 medications is possible and sometimes clinically appropriate — for example, switching
from Ozempic to Wegovy® if weight loss
is your primary goal, or to Mounjaro®
if greater weight loss outcomes are desired. Any switch must be managed by your prescriber to ensure safe dose
adjustment and monitoring.
"Ozempic face" is a popular term for the facial changes that can occur with rapid weight loss, particularly
when using GLP-1 medications like Ozempic or Wegovy. Rapid fat loss from the face can result in sunken cheeks,
hollowed under-eyes, increased visibility of wrinkles or sagging skin, and changes to the size or shape of
features like lips and chin. These effects are generally caused by fat loss itself — not by semaglutide
directly. Slower, more gradual weight loss and adequate protein intake may help minimize these changes.
Yes — through Vitercure's HIPAA-compliant telehealth program, a licensed clinician can evaluate your medical
history remotely and, if appropriate, prescribe Ozempic without an in-person visit. Ozempic is a
prescription-only medication and cannot legally be dispensed without a valid prescription from a licensed
provider. A brief online questionnaire is all that's needed to start the process.
Blood sugar may rise and appetite typically returns after stopping Ozempic, which can lead to weight regain
— especially if lifestyle changes are not maintained. Never stop suddenly without speaking to your prescriber.
They can help you taper safely or transition to another treatment plan.
What Is Ozempic and How Is It Different from Wegovy?
Ozempic and Wegovy® both contain semaglutide —
but they are different products formulated for different primary uses. Ozempic is approved by the FDA for type 2
diabetes management at doses up to 2mg per week. Wegovy is approved specifically for chronic weight management
at a higher maximum dose of 2.4mg per week — producing significantly greater average weight loss in clinical trials
(15.3% over 68 weeks in STEP-1, vs roughly 4.5–6.1 kg with Ozempic doses in the SUSTAIN trials).
For patients whose primary goal is weight loss rather than diabetes control, a prescriber may recommend Wegovy
or Mounjaro® over Ozempic. Your clinical
assessment at Vitercure covers your full health picture to guide the most appropriate choice.
Who Qualifies for Ozempic?
FDA approval covers adults with type 2 diabetes using Ozempic alongside diet and exercise. Prescribers may also use it for medically supervised weight management in patients who:
Have a BMI ≥30, or BMI ≥27 with a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol.
Have elevated A1C or insulin resistance alongside weight management goals.
Have cardiovascular risk factors — SUSTAIN-6 showed Ozempic reduced major CV events by 26% vs placebo.
Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy or severe GI disease. Your clinician will assess all of these at your Vitercure visit.
Ozempic vs Wegovy vs Mounjaro — Choosing the Right GLP-1
All three are once-weekly injectable incretins, but the right choice depends on your primary diagnosis, weight loss goals, insurance coverage and other medical conditions.
Medication
Active ingredient
Primary approval
Best for
Ozempic®
Semaglutide
Type 2 diabetes
Blood sugar control + moderate weight loss in T2D patients.
Highest average weight loss in phase 3 trials (22.5% at 15mg); dual GIP/GLP-1 mechanism.
Medically Reviewed
This content has been medically reviewed for clinical accuracy and patient safety. It is for educational
purposes and does not replace advice from your own healthcare provider.
Dr. Jane Rote, MD
Board-Certified in Endocrinology & Metabolism
Last medical review: November 2025
Content reviewed for clinical accuracy
See if Ozempic is right for you
Answer a short questionnaire online. A licensed clinician will review your information and may prescribe
Ozempic or another GLP-1 that fits your profile. No lengthy in-person visit required.
